Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27900088)

Published in Mol Clin Oncol on September 21, 2016

Authors

Fumiyasu Hanamura1, Yoshihiro Shibata2, Tsuyoshi Shirakawa3, Miyuki Kuwayama3, Hisanobu Oda4, Hiroshi Ariyama5, Kenichi Taguchi6, Taito Esaki3, Eishi Baba7

Author Affiliations

1: Department of Medical Oncology, Fukuoka Wajiro Hospital, Fukuoka 811-021, Japan; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
2: Department of Medical Oncology, Fukuoka Wajiro Hospital, Fukuoka 811-021, Japan.
3: Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
4: Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan; Department of Medical Oncology, Saiseikai Fukuoka General Hospital, Fukuoka 810-0001, Japan.
5: Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka 812-8582, Japan.
6: Department of Cancer Biology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
7: Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Articles cited by this

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98

Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg (2009) 5.38

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol (2014) 2.14

Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol (2003) 2.13

Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nat Cell Biol (2004) 1.79

Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med (2007) 1.72

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol (2012) 1.40

Prognostic and predictive factors revisited. Breast (2005) 1.39

Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract (2011) 1.28

Metastatic bone cancer as a recurrence of early gastric cancer -- characteristics and possible mechanisms. World J Gastroenterol (2005) 1.24

Bone marrow metastases. A review. Cancer (1994) 1.23

Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol (2003) 1.08

A case of bone marrow necrosis with thrombotic thrombocytopenic purpura as a manifestation of occult colon cancer. Jpn J Clin Oncol (2004) 0.99

An aggressive presentation of colorectal cancer with an atypical lymphoproliferative pattern of metastatic disease: a case report and review of the literature. Clin Colorectal Cancer (2014) 0.84

Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients. Int J Biol Markers (2004) 0.83

Recent aspects for disseminated carcinomatosis of the bone marrow associated with gastric cancer: What has been done for the past, and what will be needed in future? World J Gastroenterol (2015) 0.81

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C. Wien Klin Wochenschr (2007) 0.80

Metastatic adenocarcinoma involving the bone marrow. Blood (2012) 0.78

Bone marrow necrosis caused by metastatic colon cancer. J Clin Oncol (2009) 0.78